Refunds Coming to Theranos’s Arizona Customers

The blood-testing startup settles a legal dispute with the Arizona attorney general’s office.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, JHEUSERA day after diagnostics company Theranos announced that it had reached a settlement with the Centers for Medicare and Medicaid Services (CMS) involving conditions at its blood-testing labs in California, the company said that it had resolved another legal battle. On Tuesday (April 18), Theranos said that would be returning more than $4.5 million to Arizona consumers, to reimburse them for blood-testing services they had purchased through the firm between 2013 and 2016.

“Everyone who paid for a test will receive a full refund, period,” Mark Brnovich, the Arizona attorney general who was pursuing legal action against Theranos—alleging that the company misrepresented the methodology, accuracy, and reliability of the diagnostic tests it was selling—said in a statement. “This is a great result and a clear message that Arizona’s consumer protection laws will be vigorously enforced.”

Theranos also agreed to pay $200,000 in civil penalties to the state of Arizona and $25,000 in lawyer’s fees. Further, the firm will not operate any kind of laboratory in Arizona for a period of two years, backdated to March 28, 2017.

According to a statement released by Theranos, the company’s Arizona settlement “demonstrated the company’s commitment to resolving the issue amicably on ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies